Scientists have long known that Alzheimer’s disease slowly robs people of memory, thinking, and independence, yet the precise way it kills brain cells has remained frustratingly unclear. A new study from King’s College London suggests that a lesser-known process called karyoptosis may be a major missing link in how toxic proteins trigger neuron death in both Alzheimer’s and frontotemporal dementia. This insight into a previously overlooked mechanism of brain cell death could help shape future dementia treatments designed to slow or interrupt the loss of neurons.

Neurodegenerative conditions such as Alzheimer’s disease, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis are all marked by the buildup of misfolded or toxic proteins inside neurons. These clumps damage cells over time and are considered a hallmark of many brain disorders. Yet traditional forms of cell death, including a well-known process called apoptosis, have never fully explained why neuron loss is so extensive in these diseases. The new research highlights karyoptosis as a potentially crucial piece in this puzzle.

Karyoptosis refers to a cascade of chemical reactions that begin when toxic proteins accumulate within a cell. During this process, the cell’s nucleus, which houses its DNA, gradually shrinks and eventually breaks apart. Unlike some forms of cell death that involve dramatic cell-wide changes, karyoptosis specifically targets the nucleus. That focus on the nucleus is significant because damage to nuclear structure can disrupt essential functions such as gene expression and DNA protection, which are vital to neuron survival over a lifetime.

The study, published in Nature Communications, examined 3,000 brain cells taken from 28 people who had either frontotemporal dementia or end stage Alzheimer’s disease. Using computational algorithms, the researchers looked for evidence of different cell death pathways in this brain tissue. They identified clear signs of karyoptosis and found that it appeared much more frequently in brains affected by dementia compared with those of healthy older adults.

In the frontal cortex of people with Alzheimer’s disease, the researchers detected markers of karyoptosis in 35 percent of cells. In contrast, only 15 percent of cells from healthy older volunteers showed similar signs. That difference suggests that karyoptosis is not simply part of normal aging but may be closely linked to the disease process itself. For the King’s College London team, this finding represents the culmination of about a decade of work, starting from the first description of karyoptosis in a relatively rare condition to its recognition as a common feature in major dementias that affect millions of people worldwide.

One of the central questions the researchers set out to answer was how the accumulation of toxic proteins leads to this destructive nuclear collapse. Their work points to a chain of events that begins when misfolded proteins clump together inside neurons. This buildup appears to destabilize the outer membrane of the nucleus. As the nuclear envelope weakens, the nucleus begins to shrivel and fragment, which is characteristic of karyoptosis.

The team paid particular attention to molecules known as kinases. These are enzymes that act like switches by adding phosphate groups to other proteins, thereby turning signaling pathways on or off. Kinases often play key roles in controlling cell survival and death. In this study, the researchers examined how specific kinases interact with proteins that form the nuclear envelope and influence its stability under proteotoxic stress, the stress caused by toxic protein buildup.

In experiments using rat neurons, they found that interrupting certain kinase-driven signals reduced markers associated with karyoptosis. This suggests that, at least in a controlled laboratory environment, it is possible to slow or alter the nuclear breakdown process by targeting these molecular switches. Among the various interactions explored, the link between a kinase called p38 MAP kinase and a structural nuclear protein called LaminB1 stood out as especially promising.

LaminB1 helps maintain the shape and integrity of the nuclear envelope. The study indicates that when p38 MAP kinase interacts with LaminB1 under conditions of toxic protein stress, it contributes to the shrinking and eventual disintegration of the nucleus. Blocking or modifying this interaction in rat neurons reduced the signs of karyoptosis. While these experiments were not conducted in humans, they point to a specific molecular connection that could be relevant for therapies aimed at protecting brain cells from degeneration.

Researchers believe that this pathway, and particularly the interaction between p38 MAP kinase and LaminB1, might be developed into a target for new dementia treatments. The concept is not that a single drug would cure Alzheimer’s disease or FTD, but that by slowing or preventing karyoptosis, clinicians might reduce the rate of neuron loss. That, in turn, could give people more time before symptoms progress and could extend the window in which other disease-modifying therapies have a chance to work.

Dr. Manolis Fanto from King’s College London emphasized the potential of selectively targeting the interaction between p38 MAP kinase and LaminB1. According to his comments on the study, such an approach might slow the cell death process, effectively buying time for more precise treatments that address the underlying causes of neurodegenerative diseases. This reflects a broader strategy in dementia research: combining multiple forms of intervention, from removing toxic proteins to stabilizing vulnerable cells, to achieve better outcomes.

Senior researcher Dr. Rebecca Casterton described the work as mapping out a new series of chemical events that coordinate cell death in brain cells. Identifying the steps of karyoptosis provides a kind of road map that other scientists can follow and refine. Each step in this pathway represents a potential checkpoint where a drug, antibody, or other therapy could intervene. I found this road map idea striking because it shows how understanding the sequence of events inside a single cell may eventually translate into real-world therapies that slow a whole disease.

Dr. Sara Rodrigues from Alzheimer’s Research UK highlighted why this discovery is so important for the wider dementia research community. For decades, researchers have known that toxic proteins pile up in Alzheimer’s and frontotemporal dementia, yet the direct route from those proteins to neuron loss has remained uncertain. Putting karyoptosis on the map helps bridge that gap. Identifying this type of cell death as a major player offers concrete molecular targets for therapies aimed at stopping or slowing the loss of brain cells.

It is important to note that these findings, while compelling, represent an early step rather than an immediate cure. The study shows strong associations between karyoptosis and neurodegeneration and pinpoints particular molecular interactions that influence this cell death pathway. Translating this into safe and effective human treatments will require extensive additional research, careful testing, and clinical trials. Even so, the work adds valuable clarity in an area that has remained murky for many years.

By uncovering how proteotoxic stress can drive karyoptosis, this research helps connect the dots from misfolded proteins to nuclear damage to neuron death. It offers a detailed and testable explanation for part of the cell loss that underlies memory decline, personality changes, and other symptoms in Alzheimer’s disease and frontotemporal dementia. For people living with dementia and those who support them, these insights do not change day-to-day life yet, but they strengthen the scientific foundation on which future therapies will be built.

Read more at https://www.sciencedaily.com/releases/2026/06/260626124701.htm